StockData
Takeda Pharmaceutical Co Ltd logo

Takeda Pharmaceutical Co Ltd (TAK) stock

TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30
$20.91+0.90 (+4.50%)

Close on Oct 30, 2026Market cap $72.06BP/E –Yield –

Earnings

Takeda Pharmaceutical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Takeda Pharmaceutical's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Takeda Pharmaceutical has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Takeda Pharmaceutical puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Takeda Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K

  1. Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations
    6-K
  2. Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations
    6-K
  3. 6-K exhibit EX-99.1
    6-K
  4. [The following is the translation of the Articles of Incorporation of Takeda Pharmaceutical Company Limited, the latest amendment to which was made on 29th June 2026.]
    6-K
  5. 6-K exhibit EX-99.1
    6-K
  6. Annual Integrated Report Fiscal year ended March 31, 2026
    6-K
  7. 6-K exhibit EX-99.1
    6-K
  8. Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations
    6-K
  9. Reference: Amount Updated in FY2025 Consolidated Statements of Profit or Loss and Consolidated Statements of Financial Position
    6-K
  10. 6-K exhibit EX-99.1
    6-K
  11. 6-K exhibit EX-99.1
    6-K
  12. Takeda Pharmaceutical Company Limited Shareholder Letter from CEO-Elect Julie Kim
    6-K
  13. 6-K exhibit EX-99.1
    6-K
  14. 6-K exhibit EX-99.1
    6-K
  15. 10 of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. ###
    6-K